Scilex Holding Company

About Scilex Holding Company

Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The company aims to become the global leader in pain management, committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products that maximize quality of life.

Products & Services

ZTLido(r):Provides chronic pain relief.

Elyxyb(r):An oral solution for fast and long-lasting migraine relief.

Gloperba(r):The first liquid gout medicine designed for precision dosing.

Technology:Non-opioid pain management solutions with advanced adhesion and delivery systems.

Pipeline:A strong pipeline of non-opioid medicines under development.

Specialties

Non-opioid pain management Chronic and acute pain treatment Topical delivery systems Precision dosing solutions Migraine relief formulations

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 20300000 MR: - FA: approximately $20.3 million FAN: 20300000	D: 2025-11-25 FD: 2025-11-25	-
2	RT: Private Placement T: - FT: Private Placement	A: 20300000 MR: - FA: 20.3 million FAN: 20300000	D: 2025-11-24 FD: 2025-11-24	-
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 17000000 MR: - FA: approximately $17.0 million FAN: 17000000	D: 2024-12-13 FD: 2024-12-13	-
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 17000000 MR: - FA: approximately $17.0 million FAN: 17000000	D: 2024-12-12 FD: 2024-12-12	1 investors
5	RT: Debt T: - FT: Debt	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2024-10-08 FD: 2024-10-08	3 investors
6	RT: Convertible Debt T: - FT: Convertible Debt	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2024-10-07 FD: 2024-10-07	3 investors
7	RT: Royalty-Based Financing T: - FT: Royalty-Based Financing	A: 100000000 MR: - FA: $100M FAN: 100000000	D: 2024-06-11 FD: 2024-06-11	2 investors
8	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2024-04-25 FD: 2024-04-25	-
9	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 15000000 MR: - FA: 15 million FAN: 15000000	D: 2024-04-24 FD: 2024-04-24	1 investors
10	RT: Public Offering T: - FT: Public Offering	A: 10000000 MR: - FA: approximately $10 million FAN: 10000000	D: 2024-03-05 FD: 2024-03-05	2 investors
11	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2024-02-29 FD: 2024-02-29	2 investors
12	RT: Debt T: - FT: Debt	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2023-03-21 FD: 2023-03-21	1 investors

Warrant Exercise Latest

2025-11-25

$20.3M

Private Placement 2025-11-24

$20.3M

Registered Direct Offering 2024-12-13

$17.0M

View 11 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

H

Henry Ji

Executive Chairman, Chief Executive Officer and President

S

Stephen Ma

Chief Financial Officer & Senior Vice President

S

Suresh Khemani

Chief Commercial Officer & Senior Vice President and General Manager of Scilex Pharma

G

Gigi DeGuzman

Senior Executive Director and Chief of Staff

D

Dmitri Lissin

Interim Chief Medical Officer & Senior Vice President

S

Suketu D. Desai

Interim Chief Technical Officer and Senior Vice President, Chemistry, Manufacturing and Controls, Regulatory CMC, and Quality Assurance

View 8 more team members with Pro

Unlock Full Team Directory

Recent News